[go: up one dir, main page]

EA201992359A1 - Трициклические соединения в качестве ингибиторов киназы гликогенсинтазы-3 (gsk3) и их применение - Google Patents

Трициклические соединения в качестве ингибиторов киназы гликогенсинтазы-3 (gsk3) и их применение

Info

Publication number
EA201992359A1
EA201992359A1 EA201992359A EA201992359A EA201992359A1 EA 201992359 A1 EA201992359 A1 EA 201992359A1 EA 201992359 A EA201992359 A EA 201992359A EA 201992359 A EA201992359 A EA 201992359A EA 201992359 A1 EA201992359 A1 EA 201992359A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gsk3
compounds
kinases
glycogen synthase
application
Prior art date
Application number
EA201992359A
Other languages
English (en)
Inventor
Флоранс Феврие Вагнер
Майкл Вейвер
Артур Дж. Кэмпбелл
Джошуа Р. Захер
Эдвард Холсон
Брайан Стюарт Лукс
Тэюй Чэнь
Original Assignee
Дзе Брод Инститьют Инк.
Байоджен Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Брод Инститьют Инк., Байоджен Ма Инк. filed Critical Дзе Брод Инститьют Инк.
Publication of EA201992359A1 publication Critical patent/EA201992359A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I) и их солям, сольватам, гидратам, полиморфам, сокристаллам, таутомерам, стереоизомерам, меченным изотопами производным и их пролекарствам. Предложенные соединения могут быть полезны для ингибирования киназ, например киназы гликогенсинтазы-3 (GSK3). Предлагаемые соединения способны селективно ингибировать GSK3 по сравнению с GSK3 и/или другими киназами. Настоящее изобретение дополнительно относится к фармацевтическим композициям, наборам и способам применения, каждый из которых включает указанные соединения. Соединения, фармацевтические композиции и наборы могут быть полезными для лечения заболеваний, связанных с аберрантной активностью GSK3 (например, синдрома ломкой Х-хромосомы, синдрома дефицита внимания с гиперактивностью (СДВГ), судорожных припадков у детей, умственной отсталости, диабета, острого миелоидного лейкоза (ОМЛ), аутизма и психиатрического расстройства).
EA201992359A 2017-04-05 2018-04-05 Трициклические соединения в качестве ингибиторов киназы гликогенсинтазы-3 (gsk3) и их применение EA201992359A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481981P 2017-04-05 2017-04-05
PCT/US2018/026339 WO2018187630A1 (en) 2017-04-05 2018-04-05 Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
EA201992359A1 true EA201992359A1 (ru) 2020-03-12

Family

ID=63712671

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992359A EA201992359A1 (ru) 2017-04-05 2018-04-05 Трициклические соединения в качестве ингибиторов киназы гликогенсинтазы-3 (gsk3) и их применение

Country Status (14)

Country Link
US (2) US11203601B2 (ru)
EP (1) EP3606528B1 (ru)
JP (1) JP7157075B2 (ru)
KR (1) KR20190136063A (ru)
CN (1) CN110958882B (ru)
AU (1) AU2018249558A1 (ru)
BR (1) BR112019020810A2 (ru)
CA (1) CA3058198A1 (ru)
CO (1) CO2019012324A2 (ru)
EA (1) EA201992359A1 (ru)
IL (1) IL269701A (ru)
MX (1) MX2019011987A (ru)
SG (1) SG11201909115WA (ru)
WO (1) WO2018187630A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096594B2 (en) 2012-10-12 2015-08-04 The Broad Institute, Inc. Kinase inhibitors and methods of use thereof
CN110041349B (zh) * 2019-05-15 2021-06-01 湖南科技大学 一种含螺二氢嘧啶衍生物及其制备方法和应用
WO2023246820A1 (zh) * 2022-06-20 2023-12-28 上海优替济生生物医药有限公司 体外诱导干细胞样记忆细胞的化合物及其应用
WO2024233900A1 (en) 2023-05-10 2024-11-14 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
WO2024259178A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Glycogen synthase kinase 3 inhibitors and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2722416A1 (de) 1977-05-18 1978-11-30 Thomae Gmbh Dr K Neue thiazolo-pyridine
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JPH05157164A (ja) 1991-12-03 1993-06-22 Aisin Aw Co Ltd 車両用自動変速機のサーボ油圧制御装置
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
CN1058495C (zh) 1993-04-08 2000-11-15 杜邦药品公司 在治疗识别障碍中用作神经递质释放增强剂的多环体系类化合物及其衍生物和含有它们的药物组合物及其用途
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5750528A (en) 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
JP2005501800A (ja) 2001-02-02 2005-01-20 三菱ウェルファーマ株式会社 ジヒドロピラゾロピリジン化合物およびその医薬用途
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
JP2005505506A (ja) * 2001-06-12 2005-02-24 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用な大環状分子
RS51351B (en) 2005-07-20 2011-02-28 Aventis Pharma S.A. 1,4-DIHYDROPYRIDINE-CONDENSED HTEROCYCLES, PROCEDURES FOR THEIR PRODUCTION, USE AND THE COMPOSITIONS CONTAINING THEM
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
US8778986B1 (en) 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
WO2010098888A1 (en) 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
DE102011106990B3 (de) 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
US9096594B2 (en) 2012-10-12 2015-08-04 The Broad Institute, Inc. Kinase inhibitors and methods of use thereof
WO2015087996A1 (ja) 2013-12-13 2015-06-18 第一三共株式会社 イミダゾピリジン誘導体
KR101602559B1 (ko) 2014-04-29 2016-03-10 경북대학교 산학협력단 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도
CN107074859B (zh) 2014-09-05 2021-08-06 默克专利有限公司 用于治疗癌症的作为吲哚胺-2,3-双加氧酶(ido)拮抗剂的环己基乙基取代的二氮杂-和三氮杂-三环化合物

Also Published As

Publication number Publication date
IL269701A (en) 2019-11-28
US11203601B2 (en) 2021-12-21
SG11201909115WA (en) 2019-10-30
BR112019020810A2 (pt) 2020-04-28
EP3606528A1 (en) 2020-02-12
US20200109154A1 (en) 2020-04-09
KR20190136063A (ko) 2019-12-09
MX2019011987A (es) 2020-07-14
EP3606528A4 (en) 2020-12-23
WO2018187630A8 (en) 2019-01-03
CO2019012324A2 (es) 2020-05-15
JP7157075B2 (ja) 2022-10-19
EP3606528B1 (en) 2023-10-18
CN110958882A (zh) 2020-04-03
WO2018187630A1 (en) 2018-10-11
CN110958882B (zh) 2023-08-29
CA3058198A1 (en) 2018-10-11
US20220112216A1 (en) 2022-04-14
AU2018249558A1 (en) 2019-11-07
JP2020516616A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
EA201992359A1 (ru) Трициклические соединения в качестве ингибиторов киназы гликогенсинтазы-3 (gsk3) и их применение
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
PH12016501935A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A8 (en) Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
MX372997B (es) Compuestos de aminopirimidina como inhibidores de jak.
PH12015502248B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MX367158B (es) Benzotienilo-pirrolotriazinas disustituidas y su uso como inhibidores de quinasa fgfr.
PH12017502334A1 (en) Polycyclic amide derivative as cdk9 inhibitors
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
NZ713762A (en) Heteroaromatic compounds and their use as dopamine d1 ligands
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
WO2015058163A3 (en) Heteromaromatic compounds useful for the treatment of prolferative diseases
EA200901483A1 (ru) ПРОИЗВОДНЫЕ ПИРИМИДИНА И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
CO6321286A2 (es) Compuestos heterociclicos que contienen atomos de nitrogeno como unicos hetero atomos en el anillo en el sistema orto-condensado, y composiciones de los mismos, utiles como inhibidores de quinasa
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
BR112016015236A2 (pt) inibidores de serina/treonina quinase
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
BR112016022069A2 (pt) Composto, composição farmacêutica, e, uso de um composto
ATE522534T1 (de) Pyrrolopyrazin-kinasehemmer
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX370010B (es) Inhibidores de tirosina cinasa de bruton.
EA201001362A1 (ru) Хинолины в качестве ингибиторов фарнезилпирофосфатсинтазы
MX374759B (es) Inhibidores de tirosina cinasa de bruton.